Lanreotide Sun (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors (mainly subtypes 2 and 5) on target cells. This binding activates inhibitory signaling pathways that reduce the release of growth hormone, insulin, glucagon and various gastrointestinal hormones, thereby moderating disease activity.

The specific dose and dosing interval of lanreotide are determined by the prescribing clinician based on the patient’s condition, response to therapy and other clinical factors. Healthcare professionals follow the product label and local guidelines when selecting a regimen.

Safety data for lanreotide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Lanreotide Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Both lanreotide and octreotide are somatostatin analogs that act on the same receptor subtypes. Lanreotide is typically administered as a longer‑acting formulation, allowing less frequent injections, whereas octreotide often requires more frequent dosing. Clinical efficacy and safety profiles are comparable, but choice depends on patient preference, dosing convenience and physician judgment.

Lanreotide Sun must be stored in a refrigerator at 2 °C to 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If the temperature rises above the recommended range, discard the product according to local regulations.

Lanreotide Sun is supplied for subcutaneous injection. A healthcare professional prepares the dose according to the product label and administers it into the subcutaneous tissue, typically in the abdomen, thigh or upper arm, following aseptic technique.

Serious adverse events linked to lanreotide include gallbladder disease (such as cholecystitis or biliary sludge), pancreatitis, severe hyperglycemia, and rare anaphylactic reactions. Patients should be monitored for signs of these conditions, and therapy should be discontinued if severe reactions occur.

Lanreotide Sun is contraindicated in individuals with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for patients with uncontrolled diabetes, severe hepatic impairment, or existing gallbladder disease, and the drug should be avoided in those with a history of severe allergic reactions.